madman
Super Moderator
Make sure the tests requested are for TT/E2 (LC-MS/MS) and FT (Equilibrium Dialysis).
Need Help- New to TRT
- Thread starter braketest2
- Start date
Share this page
Make sure the tests requested are for TT/E2 (LC-MS/MS) and FT (Equilibrium Dialysis).
braketest2
Member
braketest2
Member
Good Morning everyone! Well, parts of my bloodwork are trckling in and it's early but my Hematocrit is at 56 my Hemoglobin is 17.7 and RBC is at 6.43. This all after dropping my dose to 100mg 2X from 140mg 3x. I was at 53% when Defy oredered the increase from 100 to 140. Any input? I know some common knowledge says to jump and others say not a big deal. My BP has been in a daily 130/75 - 120/70 range for the entire time. I am 68 6'3" around 200-205 lbs and not a bodybuilder but not inactive either.
Systemlord
Member
You’re most likely, either dehydrated or suffering from sleep apnea, given hemoglobin and hematocrit are so far apart.
braketest2
Member
Could you elaborate? I thought the Hemoglobin was high are you saying it's not as high as the hematocrit? Thanks!
TornCallus29
New Member
Agree with you, man. In my case it actually turned out to be sleep apnea behind some pretty bad numbers, and I was blaming everything else at first. Worth checking all possible causes instead of just guessing
braketest2
Member
Am I in a place where I should halt my TRT??? Anyone opinions?
Systemlord
Member
You should speak to your doctor whoever is managing your TRT. It was mandatory for me to do a sleep study six months after starting TRT.
The large ratio between your hematocrit and hemoglobin is indicating either dehydration or sleep apnea. I’m inclined to believe it’s the latter.
braketest2
Member
My BP has been fine and I was due to inject tonight I am only on 100mg split into 2. If you read the thread you'd notice I have been I'll advised and dosed probably poorly. Six weeks ago I was on 140mg split into 3x per week and madman convinced me to lower my dose. The last BW had me at 54 percent in January and they bumped me to 140mg. Am I wrong or should I have objected??? Hell I don't even know what to do about tonight.
Phil Goodman
Well-Known Member
The blood pressure looks good which is reassuring, but hematocrit that high would cause me to consider making changes. There are different views, but I’d generally say getting up close to 54 is about as high as I’d be willing to push it. That being said, it is just a snapshot in time and I’ve shared my experience of getting bloodwork done on a Friday and the following Monday and seeing a swing of over 3 points. Lots of things can affect that number on a test, with the main one being hydration levels. In my case I would’ve imagined I would’ve been MORE dehydrated on Monday due to drinking over the weekend, but still saw a significant drop in just a few days.
If you are getting good benefits from trt I’d say just stick with the 100 mg/weekly in two injections protocol and test hematocrit again in a few weeks. That’ll let you know if it was an outlier or if your numbers really are hovering around the 55+ range. If so, one thing to consider is going to more frequent injections as there seems to be a correlation between the height of the peak and the rise in hematocrit values. That along with hydration, exercise, and improved sleep should help. And if you’re still taking DHEA adjust that to take in the morning instead of night. Everyone reacts differently to it, and for me personally it seems to energize me so I’d imagine taking before bed would negatively affect my sleep.
Just a few things to consider before getting retested.
madman
Super Moderator
As I stated in your PM retest to rule out dehydration before jumping the gun here but keep in mind even if you were dehydrated when you had your labs done and you rehydrated next time round it would only drop down around 1-3 points and chances are your hematocrit will still be close to 54% or above.
in cases of high-end/elevated hematocrit it is always wise to rule out OSA.
If your hematocrit is >54% then you need to address it.
No need to stop therapy as there are numerous measures which can be taken.
* The monitoring schedule, the intervention ladder, and the attention to contributing factors like sleep apnea are part of what responsible, supervised testosterone replacement therapy looks like in practice. They are also what separates physiologic dosing from unsafe self-administration.
* Most current guidelines, including those from the American Urological Association and the Endocrine Society, flag hematocrit above 54% as a threshold requiring intervention. Some clinicians use 52% as a softer “watch and manage” threshold, particularly for men with additional cardiovascular risk factors.
* Men with additional risk factors (history of DVT or PE, sleep apnea, COPD, obesity, or a family history of clotting disorders) should recheck more frequently: every 3 months until the hematocrit trend is stable.
Key point here.
Sleep apnea and dehydration are often overlooked contributors that must be ruled out before changing your TRT dose
After you retest to rule out dehydration if your hematocrit is still >54% then this would apply to you.
- Clinically elevated (act required): above 54%
Normal Hematocrit Ranges and When to Act
Hematocrit is expressed as a percentage. It represents how much of your blood volume is made up of red blood cells.
Reference ranges for adult men:
- Normal: 41–53% (this varies slightly by lab)
- Borderline elevated on TRT: 52–54%
- Clinically elevated (act required): above 54%
Most current guidelines, including those from the American Urological Association and the Endocrine Society, flag hematocrit above 54% as a threshold requiring intervention. Some clinicians use 52% as a softer “watch and manage” threshold, particularly for men with additional cardiovascular risk factors.
A hematocrit value alone does not tell the whole story. Hemoglobin and hematocrit move together, and a complete blood count (CBC) gives both. Normal hemoglobin for adult men is approximately 13.5–17.5 g/dL. Elevated hemoglobin and hematocrit together confirm true erythrocytosis rather than a lab artifact.
The key thresholds in practice:
These are guidelines, not absolute cutoffs. Individual patient context, including history of clotting, baseline cardiovascular health, and symptoms, always shapes the clinical decision.
Hidden Drivers of Hematocrit Rise: What Often Gets Missed
Managing high hematocrit on TRT is not just about adjusting testosterone. Several conditions and habits significantly worsen hematocrit elevation and are frequently overlooked.
Sleep Apnea
This is the most important one. Obstructive sleep apnea (OSA) causes intermittent low oxygen levels (hypoxia) during sleep. The body responds to low nighttime oxygen the same way it responds to altitude: by producing more EPO and more red blood cells. Men with undiagnosed OSA who start TRT can see dramatic hematocrit rises because both TRT and sleep apnea are driving erythropoiesis simultaneously.
Signs of possible sleep apnea: loud snoring, gasping at night, waking unrefreshed, daytime sleepiness, or a bed partner who reports that you stop breathing. If these apply, a home sleep apnea test or referral for a sleep study is warranted before attributing the hematocrit rise entirely to testosterone.
CPAP therapy, when used consistently, often reduces hematocrit meaningfully in men with OSA on TRT. This is not a secondary benefit; it is a primary mechanism. For a deeper look at how sleep apnea intersects with mood and medication, see the related article on how sleep apnea and CPAP affect mood in a psychiatrist’s patient guide.
Hematocrit is a percentage of blood volume. When blood volume drops from dehydration, hematocrit rises even without any actual increase in red blood cell production. This is a concentration effect, not a true erythrocytosis.
Men who are chronically underhydrated, use saunas frequently, exercise heavily without replacing fluids, or take diuretics may see hematocrit values that look worse than their actual red blood cell mass would suggest. A single dehydrated CBC can drive unnecessary interventions.
Practical guidance: Draw your CBC in the morning, before heavy exercise, and with adequate hydration the prior day. If your hematocrit is borderline, recheck with better preparation before making dose changes.
The Intervention Ladder: What to Do at Each Hematocrit Level
Not all elevated hematocrit requires the same response. The stepwise approach below matches intervention to severity.
Step 1: Investigate Before Intervening (Hematocrit 52–54%)
Before changing the TRT dose, rule out reversible contributors:- Screen for sleep apnea (see above)
- Assess hydration habits and recheck CBC under better conditions if borderline
- Review smoking status
- Check for signs of COPD or chronic hypoxia
- Review injection timing and whether peak-and-trough swings are wide
If no reversible cause is found and hematocrit is persistently 52–54% or higher, the TRT protocol itself is the next target.
Reduce the dose. A lower testosterone dose typically produces lower peak levels and a smaller EPO stimulus. This is dose-dependent: the same dose that keeps one man’s hematocrit at 50% may push another’s to 55%.
Lengthen the dosing interval or switch to more frequent smaller doses. For men on injectable testosterone, high peaks drive more erythropoiesis than the average testosterone level alone. Switching from once-weekly to twice-weekly injections at the same total dose reduces peak levels and often reduces hematocrit rise. Subcutaneous injections typically produce lower, steadier levels than intramuscular injections.
Switch formulation. Transdermal testosterone (gel or patch) produces lower, more stable testosterone levels than injectable testosterone. The peak-and-trough cycle is absent. Men with persistently elevated hematocrit on injections often see normalization after switching to a transdermal formulation, even at similar average testosterone levels. Testosterone undecanoate (a long-acting injection) also produces lower peaks than standard weekly cypionate injections.
Adjust based on timing. If labs are consistently drawn at peak (shortly after injection), the hematocrit reading may be higher than mid-cycle levels. Understanding where in the injection cycle the blood was drawn is clinically relevant. It does not eliminate the need to act if levels are high, but it adds context.
When hematocrit exceeds 54–55% despite dose and formulation optimization, or when symptoms are present, therapeutic phlebotomy is indicated. This is the medical removal of a unit of blood (approximately 500 mL) to reduce red blood cell mass and lower hematocrit.
This is not the same as simply donating blood, though blood donation can serve the same purpose in eligible patients (see below). Therapeutic phlebotomy is a clinical procedure ordered by a physician, typically performed at a clinic, infusion center, or hospital outpatient setting.
One phlebotomy reduces hematocrit by approximately 3 percentage points. A single session often brings hematocrit from 57% to 53–54%. Some men require repeat phlebotomies on a scheduled basis (every 3–6 months) if hematocrit continues to rise despite TRT adjustments.
Important: Therapeutic phlebotomy depletes iron over time. Repeated phlebotomies can cause iron deficiency, which eventually limits further red blood cell production but can also cause fatigue and impair exercise capacity. Iron studies (ferritin, serum iron) should be checked regularly in men undergoing phlebotomy to avoid iron deficiency anemia.
If hematocrit rises above 56–58% despite the above steps, a temporary hold on TRT is warranted while evaluation continues. This allows hematocrit to fall. Once it normalizes, TRT can often be restarted at a lower dose or with a formulation change.
Permanent discontinuation of TRT is rarely necessary for hematocrit management alone, but it is appropriate when no dose or formulation adjustment keeps hematocrit in a safe range and other contributors have been fully addressed.
- Hematology referral: When it is unclear whether erythrocytosis is secondary to TRT or primary (such as polycythemia vera, a bone marrow disorder). Polycythemia vera can be ruled out with a JAK2 mutation test and an EPO level. In secondary erythrocytosis from TRT, EPO is elevated. In polycythemia vera, EPO is typically suppressed.
- Cardiology referral: When hematocrit elevation is accompanied by significant cardiovascular risk, prior clotting events, or symptoms that concern the prescribing provider.
- Sleep medicine referral: When sleep apnea is suspected and not yet evaluated.
braketest2
Member
I am almost ready to ditch the TRT. As we have discussed in the past I was moved up in February from 100mg 2x per week to 140 2x per week. My hematocrit was at 52 after being on 100mg since November 2025. It seems as though that was quite a jump for me to take and look how it's gone. Another thing or two I'm sure hasn't helped was I've been taking 600mg of NAC daily for months and a multivitamin with maybe too much folate. I have recently used a PPI which also was a bad idea on levothyroxine (Iam a cancer survivor) Thyroid is gone. My TSH went from normalish 2.30 for years to 8.36. Needless to say who knew? By the way when my Free T was discovered in March of 2025 my hematocrit was at 50.8 so already in the low fifties. By the way I appreciate all of you guys for pitching in! I guess beet root powder was a bad idea as well and the list goes on ....lol
Last edited:
madman
Super Moderator
By the way when my Free T was discovered in March of 2025 my hematocrit was at 50.8 so already in the low fifties.
Pretty much a given that you were going to run into issues on injectable T as your baseline was already close to 51%.
As I had pointed out to you in one of my replies in your opening thread on the forum when you first came on here that anyone with a high-end/high baseline should not start exogenous T.
This should have been addressed. before you started therapy.
As I stated earlier there are ways to address this before throwing in the towel.
* A haematocrit > 54% should require testosterone therapy withdrawal, reduction in dose, change of formulation and venesection, depending on the clinical situation, to avoid any potential cardiovascular complications. Lower baseline haematocrit (48-50%) should be carefully evaluated before testosterone therapy initiation to avoid pathological increases during treatment, especially in high-risk men, such as those with COPD or Obstructive Sleep Apnoea Syndrome (OSAS), as well as in natives living at high altitudes, since they may suffer from secondary excessive erythrocytosis [87].
Most up to date guidelines from the EAU!
EAU 2026 Guidelines on Sexual and Reproductive Health
3.4 Treatment of classical and late-onset hypogonadism
Absolute contraindications are untreated breast and prostate cancer (PCa). Similarly, conditions such as cardiovascular (CV) events as well as uncontrolled or poorly controlled congestive heart failure should be considered when prescribing testosterone therapy [85]. Conversely, severe lower urinary tract symptoms (LUTS), defined as an International Prostate Symptom Score (IPSS) > 19, represent a relative contraindication to testosterone therapy, as there is insufficient evidence regarding its long-term safety in these patients [70]. A positive family history for venous thromboembolism requires further analysis to exclude a condition of undiagnosed thrombophilia-hypofibrinolysis [86]. These patients need to be carefully counselled prior to testosterone therapy initiation. A haematocrit > 54% should require testosterone therapy withdrawal, reduction in dose, change of formulation and venesection, depending on the clinical situation, to avoid any potential cardiovascular complications. Lower baseline haematocrit (48-50%) should be carefully evaluated before testosterone therapy initiation to avoid pathological increases during treatment, especially in high-risk men, such as those with COPD or Obstructive Sleep Apnoea Syndrome (OSAS), as well as in natives living at high altitudes, since they may suffer from secondary excessive erythrocytosis [87]. Accordingly, the Framingham Heart Study showed that haematocrit > 48% represented a condition associated with increased risk of coronary artery disease and mortality, and was associated with CV disorders [88]. Testosterone therapy suppresses gonadotropin and endogenous testosterone secretion as well as spermatogenesis [89] ; therefore, testosterone therapy is contraindicated in individuals who desire fertility [90]. In this context, secondary hypogonadism is characterised by low or inappropriately normal gonadotropin levels, and the rationale is to substitute the gonadotropin deficiency with simultaneously FSH and LH analogues, if fertility is desired [91].
Key point being stressed here!
* Any elevation above the normal range for haematocrit usually becomes evident between three and 12 months after testosterone therapy initiation. However, polycythaemia can also occur after any subsequent increase in testosterone dose, switching from topical to parenteral administration, or the development of comorbidity that are linked to an increase in haematocrit (e.g. respiratory or haematological diseases).
* In cases of elevated haematocrit without comorbidities, acute CV or venous thromboembolism events, management can include reducing the testosterone dose, switching to a different formulation, or - if haematocrit is markedly high - performing venesection (500mL), repeated if necessary. In most cases, discontinuation of testosterone therapy is not required.
* With testosterone therapy, elevated haematocrit is more likely when baseline levels are near the upper limit of normal prior to initiation. Additional risk factors for increased haematocrit during therapy include smoking and pre-existing respiratory conditions. Elevated haematocrit occurs more frequently with parenteral formulations compared to topical preparations.
3.5 Safety and follow-up in hypogonadism management
3.5.6 Erythrocytosis
An elevated haematocrit is the most common adverse effect of testosterone therapy. Stimulation oferythropoiesis is a normal biological action that enhances delivery of oxygen to testosterone-sensitive tissues (e.g. striated, smooth and cardiac muscle). Any elevation above the normal range for haematocrit usually becomes evident between three and 12 months after testosterone therapy initiation. However, polycythaemia can also occur after any subsequent increase in testosterone dose, switching from topical to parenteral administration, or the development of comorbidity that are linked to an increase in haematocrit (e.g. respiratory or haematological diseases).
There is no evidence that an increase in haematocrit up to and including 54% causes any adverse effects. If haematocrit exceeds 54%, there is a testosterone-independent but weak associated rise in CV events and mortality [88, 189-191]. Any relationship is complex as these studies were based on patients with any cause of secondary polycythaemia, which included smoking and respiratory diseases. There have been no specific studies in men with only testosterone-induced erythrocytosis.
As detailed, the TRAVERSE study that included symptomatic men with hypogonadism, aged 45-80 years, who had pre-existing or high risk of CVD, showed a mild higher incidence of pulmonary embolism, a component of the adjudicated tertiary end-point of venous thromboembolic events, in the testosterone therapy than in the placebo group (0.9% vs. 0.5%) [85]. However, three previous large studies did not show any evidence that testosterone therapy is associated with an increased risk of venous thromboembolism [192, 193]. Of those, one study showed that an increased risk peaked at six months after initiation of testosterone therapy, then declined over the subsequent period [194]. In one study, venous thromboembolism was reported in 42 cases, and 40 of these had a diagnosed underlying thrombophilia (including factor V Leiden deficiency, prothrombin mutations and homocysteinuria) [195]. A meta-analysis of RCTs of testosterone therapy reported that venous thromboembolism was frequently related to underlying undiagnosed thrombophilia-hypofibrinolysis disorders [86]. In an RCT of testosterone therapy in men with chronic stable angina, there were no adverse effects on coagulation by assessment of tissue plasminogen activator or plasminogen activator inhibitor-1 enzyme activity or fibrinogen levels [196]. Similarly, another meta-analysis and systematic review of RCTs found that testosterone therapy was not associated with an increased risk of venous thromboembolism [176]. With testosterone therapy, elevated haematocrit is more likely when baseline levels are near the upper limit of normal prior to initiation. Additional risk factors for increased haematocrit during therapy include smoking and pre-existing respiratory conditions. Elevated haematocrit occurs more frequently with parenteral formulations compared to topical preparations. In line with this, a large retrospective two-arm open registry comparing long-acting testosterone undecanoate with testosterone gels found that the injectable formulation was associated with a higher risk of haematocrit levels exceeding 50%, compared to gel therapy [197]. In men with pre-existing CVD, extra caution is advised with a definitive diagnosis of hypogonadism before initiating testosterone therapy and monitoring of testosterone as well as haematocrit during treatment.
In cases of elevated haematocrit without comorbidities, acute CV or venous thromboembolism events, management can include reducing the testosterone dose, switching to a different formulation, or - if haematocrit is markedly high - performing venesection (500mL), repeated if necessary. In most cases, discontinuation of testosterone therapy is not required.
ExcelMale Newsletter Signup
Similar threads
Sponsors
Share this page
Online statistics
- Members online
- 9
- Guests online
- 1,314
- Total visitors
- 1,323
Latest posts
-
The Ultimate GLP-1 Guide: Weight Loss, Side Effects & Sarcopenia Risk- Latest: Nelson Vergel
-
When Should You Stop a GLP-1, and Who Should Never Start One?
- Latest: Nelson Vergel
-
-
-
General Peptide Use & Information- Master Index
- Latest: Nelson Vergel
-
-
Does iron deficiency affect glucose homeostasis?
- Latest: Nelson Vergel
-
-
